Pfizer Executive Previews the 8th Clinical Quality Oversight Forum in New Interview
Sunday June 18th, 2017
One of our esteemed faculty speakers recently sat down with AppliedClinicalTrialsOnline.com to discuss clinical trial quality events, which of course led to some greatly appreciated ExL conference previews! The subject of this interview is Dr. Jonathan Rowe, Executive Director and Head of Clinical Development Quality Performance and Risk Management, at Pfizer. Jonathan is speaking at our 8th Clinical Quality Oversight Forum and touches on his upcoming session in the interview.
Rowe, who recently spoke at ExL’s CROWN Congress, also answers questions regarding Pfizer’s tactics for managing clinical trial risk, how his company categorizes quality issues, the new ICH-E6 addendum, and more. Click here to read the article.
Are you interested in getting involved in the Clinical Quality Oversight Forum? To share your expertise and join the speaking faculty, contact Kristen Hunter at 212-400-6241 or email@example.com. For information on sponsorship and exhibition opportunities, contact Justin Kreamer at 212-400-6234 or firstname.lastname@example.org.
Dr. Rowe’s is leading a workshop at the 8th Clinical Quality Oversight Forum, entitled “Reviewing the ICH E6 R2 Requirements and Taking a Methodological Approach to Understanding Preparedness.” During this three-and-a-half-hour, intensive workshop session, Rowe will dive deeper into the topics touched upon in the interview mentioned above. Topics like Section 4 (Investigator) and Section 5 (Sponsor) requirements, assess compliance, GCP risk management, and more.